Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics, Inc.

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.

EcoR1 Capital

Surveyor Capital

Avalon Ventures

Hartford HealthCare Endowment

Samsara BioCapital

Biotechnology Value Fund

Bregua Corporation

BVF Partners

OrbiMed

Logos Capital

RA Capital Management

Janux Therapeutics

Today we honor Dr. Martin Luther King Jr. by taking the day to volunteer and celebrate the civil rights leader’s life and legacy. #MLKDay is the only federal holiday designated as a National Day of Service. By volunteering to improve our communities and valuing and respecting all, we honor Dr. King and work together to create a more just and equitable society. 

Visit @AmeriCorps, to find out more about #MLKDayOfService: https://lnkd.in/gX9pXAph

Congrats to Co-Founder Thomas DiRaimondo, Ph.D., on his promotion to Chief Scientific Officer!  

“Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our #TRACTr and #TRACIr platforms while supporting our clinical programs.”

We look forward to his further transformative contributions as we continue to advance our platforms and preclinical pipeline.

Read the release here: https://lnkd.in/dwGhatDa

We are grateful to our team for a great year! Janux will be closed for the holiday so we can spend time with our family and friends. We will return refreshed and ready in the New Year to continue our mission of developing meaningful new immunotherapies to improve outcomes for those fighting cancer.

#LifeatJanux #HappyHolidays

As #Movember2023 comes to a close, we want to thank everyone who joined and supported us in raising awareness for #prostatecancer and #menshealth. For Janux, #Movember helps fuel our inspiration and mission to develop meaningful new immunotherapies to improve outcomes in #mCRPC. 
 
#ProstateCancerAwareness

For International #PrideInSTEM Day, we share our support for #EqualityInSTEM and the LGBTQIA+ community 🏳️🌈. Embracing diversity, in all its forms, is vital for the future of scientific innovation.

Learn more about Pride in STEM - https://prideinstem.org/

Janux is participating in #Movember2023 to raise awareness for #prostatecancer. Here’s photos from our team members that are growing mustaches – some from Day 0 and 15! 

Early detection is key. Understand your risk and when to take action: https://lnkd.in/gPykynKt 

#prostatecancerawareness #GoJanux #Movember

Today we announced our Q3 2023 financial results and business highlights. Enrollment is ongoing for our PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) #clinicaltrials. With a strong financial foundation, we're well-positioned to advance our innovative cancer #immunotherapies.
 
Read the full press release for more details: https://lnkd.in/gmvkquyf
 
$JANX #Q3Earnings #ProstateCancer #TRACTr #TRACIr #TCellEngagers

#Movember2023 has arrived, and Janux is proud to participate in raising awareness for #menshealth and #prostatecancer. Learn more about #Movember and prostate cancer here: https://lnkd.in/gPykynKt  

We will share more progress on our mustaches 👨🦰 later in the month!  

#MensHealthAwareness #ProstateCancerAwareness #GoJanux

At Janux, we believe that each member of the team contributes to our overall mission. We succeed as a team, and we grow as a team. Come join us!

#SucceedAtJanux #GrowAtJanux

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-4.00M -	-6.78M 69.43%	-32.67M 381.60%	-63.06M 93.01%	-58.29M 7.56%
depreciation and amortization	6K -	13K 116.67%	113K 769.23%	841K 644.25%	1.96M 132.46%
deferred income tax					-277K -
stock based compensation	6K -	72K 1,100%	6.91M 9,497.22%	17.20M 148.96%	20.00M 16.29%
change in working capital	-69K -	389K 663.77%	8.84M 2,173.01%	4.28M 51.64%	-6.55M 253.27%
accounts receivables		-8M -	8M 200%
inventory		375K -	831K 121.60%
accounts payables	4K -	14K 250%	2.14M 15,178.57%	-294K 113.74%	277K 194.22%
other working capital	-73K -	8M 11,058.90%	-2.13M 126.60%	4.57M 314.76%	-6.83M 249.47%
other non cash items	233K -	1.94M 733.05%	-169K 108.71%	-2.18M 1,191.72%	-7.41M 239.49%
net cash provided by operating activities	-3.83M -	-4.37M 14.13%	-16.98M 288.56%	-42.92M 152.84%	-50.58M 17.83%
investments in property plant and equipment			-1.48M -	-6.45M 334.89%	-1.85M 71.30%
acquisitions net			339.48M -	-64.71M 119.06%
purchases of investments			-473.63M -	-294.39M 37.84%	-317.34M 7.80%
sales maturities of investments			134.15M -	359.10M 167.70%	278M 22.58%
other investing activites			-339.48M -	64.71M 119.06%
net cash used for investing activites			-340.96M -	58.27M 117.09%	-41.19M 170.70%
debt repayment	-4M -	-2.50M 37.50%
common stock issued		9.02M -	204.17M 2,162.49%	500K 99.76%	56.53M 11,206%
common stock repurchased
dividends paid
other financing activites	4M -	5M 25%	182.36M 3,547.14%		3.02M -
net cash used provided by financing activities	4M -	11.52M 188.10%	386.52M 3,254.08%	500K 99.87%	59.55M 11,809.60%
effect of forex changes on cash
net change in cash	172K -	7.16M 4,059.88%	28.59M 299.51%	15.84M 44.57%	-32.22M 303.36%
cash at beginning of period	486K -	658K 35.39%	7.81M 1,087.39%	36.40M 365.86%	52.24M 43.53%
cash at end of period	658K -	7.81M 1,087.39%	36.40M 365.86%	52.24M 43.53%	20.02M 61.68%
operating cash flow	-3.83M -	-4.37M 14.13%	-16.98M 288.56%	-42.92M 152.84%	-50.58M 17.83%
capital expenditure			-1.48M -	-6.45M 334.89%	-1.85M 71.30%
free cash flow	-3.83M -	-4.37M 14.13%	-18.46M 322.48%	-49.37M 167.46%	-52.42M 6.19%

COM:JANUXRX

Janux Therapeutics

Last Close

46.50

22/11 21:00

Market Cap

2.15B

Beta: -

Volume Today

797.30K

Avg: -

Preview